News

Mr Gandolfo has over 21 years of experience as CFO of private and publicly held companies with a primary focus in the life sciences, healthcare and medical device

Life Technologies (formerly Invitrogen) was awarded a two-year grant of nearly $870,000. The company will focus on human embryonic stem cells to create the disease models and will

In this open-label Phase II trial, quarfloxin will be administered to patients with low or intermediate grade carcinoid/neuroendocrine tumors (C/NET), including those receiving concomitant treatment with a stable

In conjunction with Dr Laikind’s resignation, the company has appointed Mark Erion, chief scientific officer and executive vice president of R&D and a member of Metabasis board of

The Phase I study was a single-center, double-blind, placebo-controlled crossover study with an open-label positive control arm to investigate the pharmacokinetic and pharmacodynamic profile of single oral doses

After review of the collected data, the independent data monitoring committee did not identify any safety concerns and has recommended that the trial continue per the protocol. This

Medidur is a tiny intravitreal insert designed to be administered by an eye care professional, using a proprietary 25-gauge inserter in a minimally invasive, outpatient procedure. This application

The data from the study demonstrate that safe and well-tolerated single doses were achieved at suggested levels and that a beneficial therapeutic index may be possible. Further clinical

Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing